Canine dermatology has witnessed a paradigm shift with the advent of Apoquel and its active ingredient, Oclacitinib. This groundbreaking medication, marked by its selective JAK inhibition characteristics, has emerged as a game-changer in the field. The success of Oclacitinib can be attributed to the meticulous chemistry work that defined the molecular properties of Oclacitinib Maleate, coupled...